A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma

  • Sabanathan, Dhanusha (Associate Investigator)
  • Chapman, Nicola (Associate Investigator)
  • Butala, Radhika (Associate Investigator)
  • Gurney, Howard (Primary Chief Investigator)

Project: Other

Project Details

Short titleAPOLLO
Effective start/end date16/05/1915/05/24